BioTime Reports Third Quarter Results and Recent Corporate Accomplishments

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the third quarter ended September 30, 2017. “BioTime achieved several significant milestones during the third quarter, both in its clinical programs and in the execution of its corporate strategy,” said Adi Mohanty, Co-Chief Executive Officer. “With the additional positive